KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Depreciation & Amortization (CF): 2009-2024

Historic Depreciation & Amortization (CF) for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to $920,000.

  • Acadia Pharmaceuticals' Depreciation & Amortization (CF) rose 0.44% to $227,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $895,000, marking a year-over-year decrease of 11.12%. This contributed to the annual value of $920,000 for FY2024, which is 38.67% down from last year.
  • Acadia Pharmaceuticals' Depreciation & Amortization (CF) amounted to $920,000 in FY2024, which was down 38.67% from $1.5 million recorded in FY2023.
  • Over the past 5 years, Acadia Pharmaceuticals' Depreciation & Amortization (CF) peaked at $2.2 million during FY2021, and registered a low of $920,000 during FY2024.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $1.5 million (2023), whereas its average is $1.5 million.
  • In the last 5 years, Acadia Pharmaceuticals' Depreciation & Amortization (CF) spiked by 49.07% in 2021 and then plummeted by 38.67% in 2024.
  • Yearly analysis of 5 years shows Acadia Pharmaceuticals' Depreciation & Amortization (CF) stood at $1.5 million in 2020, then spiked by 49.07% to $2.2 million in 2021, then declined by 9.39% to $2.0 million in 2022, then decreased by 25.96% to $1.5 million in 2023, then slumped by 38.67% to $920,000 in 2024.